Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stifel Downgrades Chinook Therapeutics to Hold, Lowers Price Target to $41

Author: Benzinga Newsdesk | June 13, 2023 07:25am
Stifel analyst Alex Thompson downgrades Chinook Therapeutics (NASDAQ:KDNY) from Buy to Hold and lowers the price target from $43 to $41.

Posted In: KDNY

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist